{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:25:13Z","timestamp":1768713913698,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13256-017-1515-9","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T09:52:48Z","timestamp":1514541168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pulmonary arterial hypertension in a patient treated with dasatinib: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Andris","family":"Skride","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matiss","family":"Sablinskis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristaps","family":"Sablinskis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Lesina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aivars","family":"Lejnieks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lejniece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"crossref","unstructured":"Galie N, Humbert M, Vachiery JL, Simon Gibbs, Irene Lang\u00a0et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"1515_CR2","first-page":"281","volume":"5","author":"DG Aguilera","year":"2009","unstructured":"Aguilera DG, Tsiberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009;5:281\u20139.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"1515_CR3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4143\/crt.2013.155","volume":"47","author":"H Ji Hyung","year":"2015","unstructured":"Ji Hyung H, Sung-Eun L, Soo Young C, Soo-Hyun K, Eun-Jung J, Ju-Hee B, et al. Reversible pulmonary arterial hypertension associated with Dasatinib for chronic myeloid leukemia. Cancer Res Treat. 2015;47(4):937\u201342.","journal-title":"Cancer Res Treat"},{"issue":"20","key":"1515_CR4","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients. Trial J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"Trial J Clin Oncol"},{"issue":"24","key":"1515_CR5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"key":"1515_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","volume":"3","author":"W Guoqing","year":"2010","unstructured":"Guoqing W, Shamudheen R, Delong L. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3:47.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1515_CR7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1515_CR8","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94 Suppl 2:S141\u20137.","journal-title":"Ann Hematol"},{"issue":"4","key":"1515_CR9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494\u2013500.","journal-title":"Blood"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-017-1515-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T09:53:11Z","timestamp":1514541191000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-017-1515-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1186\/s13256-017-1515-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"362"}}